#1 Clinical Trials Search in Europe

Unsaturated Fatty Acids (C18 : 2)

This article discusses a clinical trial investigating the effectiveness of a novel moisturizer containing unsaturated fatty acids (C18:2) in preventing eczema relapse in children with atopic dermatitis. The study aims to compare this new moisturizer to a reference cream and evaluate its impact on disease severity, quality of life, and skin microbiome.

Table of Contents

What is UNSATURATED FATTY ACIDS (C18:2)?

UNSATURATED FATTY ACIDS (C18:2), also known as linoleic acid, is a type of fat that is liquid at room temperature. It’s an important component in a moisturizer called Linola Fett, which is being studied for its potential benefits in treating atopic dermatitis, also known as eczema[1]. Atopic dermatitis is a common skin condition that causes dry, itchy, and inflamed skin.

Medical Use and Benefits

The main purpose of using UNSATURATED FATTY ACIDS (C18:2) in the form of Linola Fett cream is to prevent eczema from coming back (relapsing) in children. Researchers believe this moisturizer might be better than other creams at keeping eczema under control[1]. The cream is designed to:

  • Keep the skin moisturized
  • Reduce itching and inflammation
  • Help maintain healthy skin and prevent eczema flare-ups

Current Clinical Trial

A clinical trial called NOVA II is currently studying how well Linola Fett works compared to other creams for children with atopic dermatitis. This trial aims to[1]:

  • Show that Linola Fett is better at preventing eczema from coming back in children
  • Study how severe the eczema is at different stages
  • Look at how the treatment affects quality of life
  • See how satisfied patients and parents are with the treatment
  • Check how well people like using the cream (its feel, smell, etc.)
  • Explore how the cream affects the skin’s microbiome (the tiny organisms living on the skin)

How It’s Applied

Linola Fett is a cream that is applied directly to the skin (topically). In the clinical trial, children use up to 4 ml of the cream per day, with a maximum total amount of 112 ml over a 4-week period[1]. It’s important to follow the instructions given by your doctor or the study team when using this or any medication.

Who Can Use This Treatment?

The clinical trial has specific criteria for who can participate. These include[1]:

  • Children between 2 and 12 years old
  • Diagnosed with atopic dermatitis
  • Have mild to moderate eczema
  • Have had at least two eczema flare-ups in the last 12 months

There are also conditions that would prevent a child from participating, such as having very severe eczema, certain other medical conditions, or using certain other treatments.

Measuring Effectiveness

The study will measure how well Linola Fett works in several ways[1]:

  • How long it takes for eczema to come back (if it does)
  • How many children still don’t have eczema after 1, 2, 3, 4, 5, and 6 months of treatment
  • How severe the eczema is, using special scoring systems (like PO-SCORAD and POEM)
  • How itchy the skin is
  • How the treatment affects quality of life

Safety and Side Effects

While the study is still ongoing, the researchers are carefully monitoring the safety of Linola Fett. They’re looking at[1]:

  • How well people tolerate the cream
  • If it causes any stinging or smarting when applied
  • Any side effects that occur during the study

It’s important to note that all medications can have potential side effects, and what works for one person may not work the same way for another. Always consult with a healthcare professional before starting any new treatment.

Aspect Details
Study Type Phase IV randomized, double-blind, parallel-design, controlled multi-center trial
Participants Children aged 2-12 years with atopic dermatitis
Intervention Novel moisturizer containing unsaturated fatty acids (C18:2)
Comparison Reference cream
Primary Outcome Relapse of atopic eczema (hazard ratio)
Secondary Outcomes Time to relapse, disease severity, quality of life, cream consumption, tolerability
Duration Up to 6 months maintenance phase
Additional Investigations FLG mutations, skin microbiome changes

FAQ

  • What is the main goal of this clinical trial? The main goal is to demonstrate the superiority of a newly developed moisturizer in preventing eczema relapse in children with atopic dermatitis compared to a reference cream.
  • Who can participate in this clinical trial? Children between 2 and 12 years old with a diagnosis of atopic dermatitis, mild to moderate eczema, and at least two relapses during the last 12 months can participate.
  • What will be measured during the trial? The trial will measure relapse of atopic eczema, time to relapse, disease severity, quality of life, cream consumption, and tolerability of the products.
  • How long does the maintenance phase of the trial last? The maintenance phase of the trial lasts up to 6 months, with assessments made at 1, 2, 3, 4, 5, and 6 months.
  • What is unique about the moisturizer being tested? The moisturizer being tested contains unsaturated fatty acids (C18:2) and is a novel formulation developed specifically for preventing eczema relapse in children with atopic dermatitis.

Ongoing Clinical Trials on Unsaturated Fatty Acids (C18 : 2)

  • Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Sweden

Glossary

  • Atopic dermatitis: A chronic inflammatory skin condition characterized by itchy, dry, and inflamed skin, commonly known as eczema.
  • SCORAD: SCORing Atopic Dermatitis, a tool used to assess the extent and severity of eczema.
  • PO-SCORAD: Patient-Oriented SCORAD, a self-assessment tool for patients to measure their eczema severity.
  • POEM: Patient-Oriented Eczema Measure, a questionnaire used to assess eczema symptoms.
  • RECAP: Recap of atopic eczema, a weekly assessment tool for measuring disease severity.
  • IDQoL: Infants' Dermatitis Quality of Life Index, used to assess quality of life in children under 4 years old with eczema.
  • CDLQI: Children's Dermatology Life Quality Index, used to assess quality of life in children over 4 years old with skin conditions.
  • FLG: Filaggrin gene, associated with skin barrier function and atopic dermatitis.
  • Microbiome: The collection of microorganisms living on and in the human body, including the skin.
  • Unsaturated Fatty Acids (C18:2): A type of fatty acid with 18 carbon atoms and 2 double bonds, used in the novel moisturizer being tested in this trial.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effect-of-a-new-moisturiser-with-paraffin-and-liquid-paraffin-on-preventing-eczema-relapse-in-children/